Resverlogix Corp. (RVX.TO)
CAD 0.05
(12.5%)
CAD 0.05
(12.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -11.74 Million USD | 21.02% |
| 2021 | -14.86 Million USD | -104593.5% |
| 2020 | -14.2 Thousand USD | 99.98% |
| 2019 | -74.15 Million USD | -192943.84% |
| 2018 | -38.41 Thousand USD | 99.87% |
| 2017 | -30.54 Million USD | -5.98% |
| 2016 | -28.81 Million USD | -9.93% |
| 2015 | -26.21 Million USD | -840.96% |
| 2014 | 3.53 Million USD | -95.18% |
| 2013 | 73.4 Million USD | 179.62% |
| 2012 | 26.25 Million USD | 208.57% |
| 2011 | -24.18 Million USD | -10.83% |
| 2010 | -21.81 Million USD | 0.09% |
| 2009 | -21.83 Million USD | -15.27% |
| 2008 | -18.94 Million USD | 22.22% |
| 2007 | -24.35 Million USD | -58.52% |
| 2006 | -15.36 Million USD | -150.38% |
| 2005 | -6.13 Million USD | -122.68% |
| 2004 | -2.75 Million USD | -114.59% |
| 2003 | -1.28 Million USD | -161.99% |
| 2002 | -490.2 Thousand USD | -1151.22% |
| 2001 | -39.17 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -1406.00 USD | 99.94% |
| 2023 Q2 | -1.38 Million USD | -98050.78% |
| 2023 Q3 | -911 Thousand USD | 33.99% |
| 2022 Q1 | -5.67 Million USD | -5.82% |
| 2022 Q2 | -1.75 Million USD | 69.03% |
| 2022 Q3 | -2 Million USD | -14.28% |
| 2022 FY | - USD | 21.02% |
| 2022 Q4 | -2.29 Million USD | -14.44% |
| 2021 Q2 | -3.17 Million USD | -131.22% |
| 2021 Q1 | -1.37 Million USD | 0.0% |
| 2021 FY | - USD | -104593.5% |
| 2021 Q4 | -5.36 Million USD | -8.32% |
| 2021 Q3 | -4.95 Million USD | -55.87% |
| 2020 Q3 | -1.36 Million USD | 48.35% |
| 2020 FY | - USD | 99.98% |
| 2020 Q1 | -1.37 Million USD | 70.95% |
| 2020 Q2 | -2.63 Million USD | -91.35% |
| 2019 Q4 | -4.73 Million USD | 95.94% |
| 2019 Q3 | -116.63 Million USD | -394.27% |
| 2019 Q2 | -23.59 Million USD | -153.36% |
| 2019 Q1 | 44.22 Million USD | 757.86% |
| 2019 FY | - USD | -192943.84% |
| 2018 Q3 | 15.88 Million USD | -51.26% |
| 2018 Q4 | -6.72 Million USD | -142.31% |
| 2018 Q1 | -12.6 Million USD | -331.17% |
| 2018 Q2 | 32.6 Million USD | 358.68% |
| 2018 FY | - USD | 99.87% |
| 2017 FY | - USD | -5.98% |
| 2017 Q4 | -2.92 Million USD | 72.43% |
| 2017 Q3 | -10.6 Million USD | -140.27% |
| 2017 Q2 | -4.41 Million USD | 54.56% |
| 2017 Q1 | -9.71 Million USD | -20.44% |
| 2016 Q3 | -1.65 Million USD | 82.34% |
| 2016 Q1 | -7.04 Million USD | -247.41% |
| 2016 Q2 | -9.38 Million USD | -33.13% |
| 2016 FY | - USD | -9.93% |
| 2016 Q4 | -8.06 Million USD | -386.66% |
| 2015 Q3 | -5.92 Million USD | 47.13% |
| 2015 Q4 | -2.02 Million USD | 65.77% |
| 2015 FY | - USD | -840.96% |
| 2015 Q2 | -11.21 Million USD | -158.53% |
| 2015 Q1 | 19.15 Million USD | 600.86% |
| 2014 Q1 | 7.19 Million USD | -63.95% |
| 2014 FY | - USD | -95.18% |
| 2014 Q3 | -683 Thousand USD | -106.1% |
| 2014 Q4 | -3.82 Million USD | -459.88% |
| 2014 Q2 | 11.2 Million USD | 55.72% |
| 2013 FY | - USD | 179.62% |
| 2013 Q3 | 3.43 Million USD | -91.99% |
| 2013 Q4 | 19.95 Million USD | 481.67% |
| 2013 Q2 | 42.85 Million USD | 652.7% |
| 2013 Q1 | 5.69 Million USD | 26.79% |
| 2012 FY | - USD | 208.57% |
| 2012 Q4 | 4.49 Million USD | 154.42% |
| 2012 Q3 | -8.25 Million USD | 1.69% |
| 2012 Q2 | -8.39 Million USD | -25.56% |
| 2012 Q1 | -6.68 Million USD | -27.57% |
| 2011 Q4 | -5.24 Million USD | 44.76% |
| 2011 FY | - USD | -10.83% |
| 2011 Q2 | -9.66 Million USD | -45.44% |
| 2011 Q3 | -9.48 Million USD | 1.88% |
| 2011 Q1 | -6.64 Million USD | -49.19% |
| 2010 Q3 | -5.28 Million USD | -0.68% |
| 2010 Q4 | -4.45 Million USD | 15.72% |
| 2010 FY | - USD | 0.09% |
| 2010 Q1 | -5.5 Million USD | 29.77% |
| 2010 Q2 | -5.25 Million USD | 4.52% |
| 2009 Q2 | -4.57 Million USD | -22.9% |
| 2009 Q4 | -7.83 Million USD | -103.4% |
| 2009 Q3 | -3.85 Million USD | 15.81% |
| 2009 Q1 | -3.72 Million USD | 23.5% |
| 2009 FY | - USD | -15.27% |
| 2008 Q3 | -4.66 Million USD | -13.1% |
| 2008 Q1 | -7.11 Million USD | -32.6% |
| 2008 Q2 | -4.12 Million USD | 42.03% |
| 2008 Q4 | -4.86 Million USD | -4.25% |
| 2008 FY | - USD | 22.22% |
| 2007 Q2 | -5.33 Million USD | 29.95% |
| 2007 Q4 | -5.36 Million USD | 18.06% |
| 2007 Q3 | -6.54 Million USD | -22.75% |
| 2007 Q1 | -7.61 Million USD | -116.93% |
| 2007 FY | - USD | -58.52% |
| 2006 FY | - USD | -150.38% |
| 2006 Q4 | -3.51 Million USD | -28.03% |
| 2006 Q3 | -2.74 Million USD | -61.4% |
| 2006 Q1 | -1.98 Million USD | -62.64% |
| 2006 Q2 | -1.69 Million USD | 14.44% |
| 2005 Q2 | -1.07 Million USD | -16.79% |
| 2005 FY | - USD | -122.68% |
| 2005 Q4 | -1.22 Million USD | 29.01% |
| 2005 Q3 | -1.71 Million USD | -60.27% |
| 2005 Q1 | -918.88 Thousand USD | -3.35% |
| 2004 Q4 | -889.12 Thousand USD | -237.99% |
| 2004 Q2 | -414.94 Thousand USD | 39.67% |
| 2004 Q1 | -687.76 Thousand USD | -231.34% |
| 2004 FY | - USD | -114.59% |
| 2004 Q3 | -263.06 Thousand USD | 36.6% |
| 2003 Q3 | -114.85 Thousand USD | 55.29% |
| 2003 Q2 | -256.9 Thousand USD | -11.37% |
| 2003 FY | - USD | -161.99% |
| 2003 Q4 | -207.57 Thousand USD | -80.72% |
| 2003 Q1 | -230.68 Thousand USD | -98.73% |
| 2002 Q3 | -12.95 Thousand USD | 49.44% |
| 2002 Q4 | -116.07 Thousand USD | -796.03% |
| 2002 FY | - USD | -1151.22% |
| 2002 Q1 | -4777.27 USD | 0.0% |
| 2002 Q2 | -25.62 Thousand USD | -436.37% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Appili Therapeutics Inc. | -2.09 Million CAD | -460.109% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 68.6% |
| Helix BioPharma Corp. | -9.38 Million CAD | -25.061% |
| Microbix Biosystems Inc. | 1.95 Million CAD | 699.98% |
| Medicenna Therapeutics Corp. | -18.67 Million CAD | 37.108% |
| Satellos Bioscience Inc. | -15.7 Million CAD | 25.234% |
| Oncolytics Biotech Inc. | -33.71 Million CAD | 65.168% |
| Sernova Corp. | -40.19 Million CAD | 70.786% |